SciBase Expands Its Intellectual Property Portfolio to include the analysis of the epithelial skin barrier with New European Patent

SciBase Holding AB announced on Dec. 11, 2025 that the European Patent Office granted EP3876835B1, covering in‑vivo electrical impedance methods to assess and monitor the epithelial skin barrier—including detecting drug effects, patient response to barrier delivery, and screening methods robust to environmental factors; the patent runs until 2039 and covers PCT protection in Europe. The grant expands SciBase’s IP estate around its AI-enabled Nevisense diagnostics, reinforcing its technological moat and positioning for commercial deployment, research collaborations and potential licensing opportunities in skin‑barrier and dermatology applications.

Analysis

SciBase Holding AB announced on December 11, 2025 that the European Patent Office granted EP3876835B1, titled "Medical Devices for Analyzing Epithelial Barrier Function", covering in‑vivo electrical impedance measurements to assess and monitor the epithelial skin barrier. The patent specifically includes detecting drug effects, determining patient response to epithelial skin barrier delivery, an improved in‑vivo screening device and methods designed to be stable against environmental factors; the grant covers PCT protection in the European region and expires in 2039.

The patent strengthens SciBase’s intellectual property around its AI-enabled Nevisense platform and aligns with the company’s stated strategic focus on developing medical and research solutions for epithelial barrier function, with the company citing collaboration with Professor Cezmi Akdis and naming DNB Carnegie as its certified adviser. SciBase is positioned as a specialist in early dermatology diagnostics and highlights the role of AI plus electrical impedance spectroscopy in its point-of-care offering.

The grant is mildly positive for the company’s technological moat and creates clearer pathways for licensing, research partnerships and product differentiation, consistent with the provided sentiment and market‑impact signals. Material risks remain: the protection is Europe‑focused, the patent expires in 2039, and value realization depends on commercialization, clinical adoption, regulatory progress and demonstrable revenue conversion rather than the grant alone.

Key Decisions for Investors

• Consider a modestly positive stance given the strengthened IP; avoid large position increases solely on the patent grant because it does not immediately alter revenue prospects
• Monitor for concrete catalysts—licensing agreements, commercial partnerships, published clinical validation of Nevisense in epithelial barrier applications, and regulatory clearances—and increase exposure only if those milestones are achieved
• Limit downside risk by sizing positions conservatively until SciBase demonstrates commercialization traction or broader IP coverage beyond the European PCT region, and reassess if the company communicates a clear monetization plan